Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.3 USD | -0.43% | +2.14% | -4.77% |
05-03 | Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate | MT |
05-03 | J&J: to present advances in retinal diseases | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.77% | 361B | |
+26.08% | 681B | |
+21.85% | 556B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B | |
+8.08% | 149B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Reaffirms 2022 Adjusted Operational Sales, Earnings Outlook; Unveils $5 Billion Share-Buyback Plan